Asia Pacific Semaglutide Market Size & Outlook, 2026-2035
Global Market
Related Markets
Asia Pacific semaglutide market highlights
- The Asia Pacific semaglutide market generated a revenue of USD 2,999.8 million in 2025.
- The market is expected to grow at a CAGR of 12.33% from 2026 to 2035.
- In terms of segment, ozempic (semaglutide) was the largest revenue generating product in 2025.
- Rybelsus (oral semaglutide) is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Japan is expected to register the highest CAGR from 2026 to 2035.
Asia Pacific data book summary
| Market revenue in 2025 | USD 2,999.8 million |
| Market revenue in 2035 | USD 10,055.5 million |
| Growth rate | 12.33% (CAGR from 2026 to 2035) |
| Largest segment | Ozempic (semaglutide) |
| Fastest growing segment | Rybelsus (oral semaglutide) |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2035 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ozempic (semaglutide), Wegovy (semaglutide), Rybelsus (oral semaglutide) |
| Key market players worldwide | Novo Nordisk A/S ADR, Eli Lilly and Co, Viking Therapeutics Inc, Lexicon Pharmaceuticals, Biocon, AstraZeneca PLC |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 8.7% of the global semaglutide market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2035.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 10,055.5 million by 2035.
The Asia-Pacific semaglutide market is witnessing rapid expansion, driven by rising obesity and diabetes prevalence, increasing healthcare investments, and regulatory approvals for GLP-1 therapies.
China, Japan, and India lead the market, supported by domestic pharmaceutical manufacturing and growing patient awareness. The region is experiencing increasing adoption of semaglutide in both hospital and retail pharmacy settings.
No credit card required*
Publish Date: Apr 16, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Semaglutide Market Scope
Semaglutide Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Novo Nordisk A/S ADR | View profile | 66,015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | www.novonordisk.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Biocon | View profile | 10001+ | Bangalore, Karnataka, India, Asia | www.biocon.com |
| Viking Therapeutics Inc | View profile | 28 | 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, United States, 92121 | www.vikingtherapeutics.com |
| Lexicon Pharmaceuticals | View profile | 101-250 | The Woodlands, Texas, United States, North America | www.lexpharma.com |
Asia Pacific Semaglutide Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Semaglutide Market Outlook will help companies and investors design strategic landscapes.
Ozempic (Semaglutide) was the largest segment with a revenue share of 59.8% in 2025.
Horizon Databook has segmented the Asia Pacific semaglutide market based on ozempic (semaglutide), wegovy (semaglutide), rybelsus (oral semaglutide) covering the revenue growth of each sub-segment from 2021 to 2035.
The Asia-Pacific semaglutide market is witnessing rapid expansion, driven by rising obesity and diabetes prevalence, increasing healthcare investments, and regulatory approvals for GLP-1 therapies.
China, Japan, and India lead the market, supported by domestic pharmaceutical manufacturing and growing patient awareness. The region is experiencing increasing adoption of semaglutide in both hospital and retail pharmacy settings.
- Asia Pacific Semaglutide Market Product Outlook (Revenue, USD Million , 2021-2035)
- Ozempic (semaglutide)
- Wegovy (semaglutide)
- Rybelsus (oral semaglutide)
- Others
- Asia Pacific Semaglutide Market Application Outlook (Revenue, USD Million , 2021-2035)
- Type 2 Diabetes Mellitus
- Obesity
- Asia Pacific Semaglutide Market Route of Administration Outlook (Revenue, USD Million , 2021-2035)
- Parenteral
- Oral
- Asia Pacific Semaglutide Market Distribution Channel Outlook (Revenue, USD Million , 2021-2035)
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Reasons to subscribe to Semaglutide Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Semaglutide Market Outlook databook
- Our clientele includes a mix of Semaglutide Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Semaglutide Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Semaglutide Market Outlook from 2021 to 2035, including revenue numbers, major trends, and company profiles.
Asia Pacific Semaglutide Market, 2021-2035 (US$M)
Asia Pacific semaglutide market statistics, by product, 2021-2035 (US$M)
